Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HS-20089 + bevacizumab versus investigator's choice platinum-based chemotherapy + bevacizumab in platinum-sensitive recurrent ovarian cancer
CTR20263419Phase 3Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mocertatug rezetecan, bevacizumab in ovarian cancer, sponsored by Hansoh Pharmaceutical Group. Started Oct 2026; status: active.
02
Drugs
mocertatug rezetecanbevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on CTR20263419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263419.